Use of a Sustainable Livelihood Framework-Based Measure to Estimate Socioeconomic Impact of Tuberculosis on Households.
coping strategies
impoverishment
sustainable livelihood
tuberculosis
well-being
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
11 09 2023
11 09 2023
Historique:
received:
13
01
2023
medline:
13
9
2023
pubmed:
3
5
2023
entrez:
3
5
2023
Statut:
ppublish
Résumé
Tuberculosis (TB) disproportionally affects impoverished members of society. The adverse socioeconomic impact of TB on households is mostly measured using money-centric approaches, which have been criticized as one-dimensional and risk either overestimating or underestimating the true socioeconomic impacts of TB. We propose the use of the sustainable livelihood framework, which includes 5 household capital assets (human, financial, physical, natural, and social) and conceptualizes that households employ accumulative strategies in times of plenty and coping (survival) strategies in response to shocks such as TB. The proposed measure ascertains to what extent the 5 capital assets are available to households affected by TB as well as the coping costs (reversible and nonreversible) that are incurred by households at different time points (intensive, continuation, and post-TB treatment phase). We assert that our approach is holistic and multidimensional and draws attention to multisectoral responses to mitigate the socioeconomic impact of TB on households.
Identifiants
pubmed: 37132328
pii: 7149871
doi: 10.1093/cid/ciad273
pmc: PMC10495125
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
761-767Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : FIC NIH HHS
ID : D43 TW009539
Pays : United States
Organisme : Wellcome Trust
ID : 206316_Z_17_Z
Pays : United Kingdom
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. K. K. reports grants or contracts from the European and Developing Countries Clinical Trials Partnership (ERASE-TB and VITALITY), the Wellcome Trust (impact of the typhoid conjugate vaccine), the Bill & Melinda Gates Foundation, and the China Center for Disease Control and Prevention (investigating COVID-19 vaccine effectiveness). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Thorax. 2021 Apr;76(4):387-395
pubmed: 33443228
Emerg Infect Dis. 2020 May;26(5):989-992
pubmed: 32310069
BMC Infect Dis. 2016 Jun 21;16:307
pubmed: 27329161
Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1129-1130
pubmed: 31718747
Eur Respir J. 2014 Jun;43(6):1763-75
pubmed: 24525439
PLoS One. 2022 Apr 26;17(4):e0266356
pubmed: 35472210
Trials. 2014 Jun 19;15:236
pubmed: 24947537
Soc Sci Med. 2018 Oct;215:7-15
pubmed: 30196149
Lancet Infect Dis. 2019 Nov;19(11):1170-1171
pubmed: 31657778
Int J Tuberc Lung Dis. 2019 Jan 1;23(1):1-2
pubmed: 30674372
Int J Tuberc Lung Dis. 2019 Jan 1;23(1):5-11
pubmed: 30674374
PLOS Glob Public Health. 2023 Aug 7;3(8):e0001706
pubmed: 37549111
PLoS One. 2021 Jul 16;16(7):e0254204
pubmed: 34270593
Qual Health Res. 2019 Jul;29(8):1109-1119
pubmed: 30499375
BMC Public Health. 2021 Nov 11;21(1):2065
pubmed: 34763696
Health Policy Plan. 1996 Sep;11(3):219-37
pubmed: 10160370